News

How do you pick an LAI antipsychotic? Molecule first, delivery system second, Jacob Hanaie, PharmD, shared at SoCal Psychiatry.

At the Southern California Psychiatry Conference, Jason Kellogg, MD, shares insights into the evolution of the MDD pipeline, with an eye on rapid-acting novel mechanisms.

Phase 3 data show COMP360 psilocybin delivers rapid, lasting relief in treatment-resistant depression; FDA filing advances toward 2027 launch.

Open-label phase 2 trial tests IV Briumvi alongside antipsychotics for treatment-resistant schizophrenia, targeting B-cell depletion to improve symptoms and assess safety.

Share insights on substance use care—practice tips, research, and cases—for Psychiatric Times’ July 2026 series. Pitch your article today.

Psychiatrists debunk 10 common antidepressant myths—placebo claims, addiction fears, suicide risk, overuse, and withdrawal—offering evidence-based guidance.

Phase 3b trial shows centanafadine eases adult ADHD and anxiety symptoms fast, with expected safety profile, as FDA review nears.

AI may assist psychopharmacology by aiding suicide risk, digital phenotyping, and TRD care—while exposing EHR data limits and the need for smarter integration.

Track latest neuropsychiatry breakthroughs: phase 3 narcolepsy study launches, new depression and PTSD therapies advance, and FDA approvals reshape care.

Check out the pipeline updates from June!

Largest real-world analysis shows Deep TMS cuts PTSD and depression symptoms in comorbid patients; promising but not FDA-cleared yet.

Transgender psychiatrists of color share APA first-panel insights on identity, allyship, and gender-affirming care—urging intersectional, culturally engaged mental health practice.

Estrogen shapes schizophrenia in women: onset peaks, dosing shifts, and relapse risk from periods to pregnancy, postpartum, and menopause.

Adults born with congenital heart disease face hidden anxiety, PTSD, and cognitive hurdles. See why embedding psychiatry in cardiac care changes outcomes.

Learn how CYP450 genetics, phase 2 metabolism, and drug interactions shape psychiatric dosing—what’s actionable now and what’s next in PPGx.

Phase 2 IRIS finds ML-004 misses social communication goals in autism, but notably reduces irritability in teens.

FDA issues CRL for cytisinicline, citing manufacturing issues.

Phase 3 results show single-dose DT120 lysergide ODT delivers rapid, lasting relief in major depressive disorder with mild, transient adverse effects.

Learn how cognitive remediation, aerobic exercise, and reducing secondary risks can boost thinking skills and daily functioning in schizophrenia.

Key steps for first-episode psychosis: team-based care, low-dose meds, relapse planning, family support, and cannabis harm reduction.

Midlife sleep trouble predicts poorer well-being 9 years later, especially for women. Here's why clinicians should ask about sleep and menopause triggers.

Learn a multidimensional approach to suicide prevention in schizophrenia—screening, insight paradox, cannabis, cognition, trauma, and ethical AI monitoring.

"I’m a four-year-old prince with a bag of Jack Frost sand filling my sandbox kingdom..."

Teens’ pre-bed smartphone scrolling drives more late-night phone use, disrupting sleep and potentially worsening mental health—experts urge bedtime screen limits and device-free bedrooms.

Meta-analysis finds intranasal esketamine boosts remission in MDD and TRD fast, but side effects and short trials leave long-term questions.

Once-nightly regular-release lithium cuts kidney risk, maintains bipolar control, improves adherence, and guides safer serum levels.

Why psychiatrists must talk about sex: sexual dysfunction can exacerbate comorbid psychiatric disorders and contribute to medication nonadherence.

AbbVie’s short-acting psychedelic bretisilocin shows rapid MADRS drops in phase 2a MDD trials, hinting at scalable, supervised depression care.

Explore the brain’s 5 monoamines—beyond serotonin and dopamine—revealing histamine, melatonin, and trace amines shaping sleep, appetite, and mood.

Explore 2026’s fast-moving psych med pipeline: new Alzheimer agitation option, potential novel ADHD therapy, and promising psilocybin for depression.